Intra-Cellular Therapies, Inc. (ITCI)

Trade ITCI now with
5/10/2021 8:05:27 AM Intra-Cellular Therapies Q1 Net Loss $52.7 Mln Vs Loss Of $47.4 Mln Last Year
4/12/2021 7:39:29 AM Intra-Cellular Therapies Presents Data On Antitumor Effects Of PDE1 Inhibition In A Preclinical Colorectal Cancer Model
12/29/2020 8:17:16 AM Intra-Cellular Therapies Begins Clinical Programs For ITI-LLAI And For ITI-333
9/10/2020 11:24:39 PM Intra-Cellular Therapies Prices Public Offering Of 11.67 Mln Shares At $30.00/shr
6/29/2020 8:28:32 AM Intra-Cellular Therapies Reports Positive Top-line Results From ITI-214 Phase I/II Study
4/2/2020 8:19:36 AM Intra-Cellular Therapies Begins Promotional Activities For CAPLYTA
3/23/2020 7:36:18 AM Intra-Cellular Therapies Announces Availability Of CAPLYTA For Adult Patients With Schizophrenia
1/7/2020 11:33:03 PM Intra-Cellular Therapies Prices Public Offering Of 10 Mln Shares At $29.50/Shr
2/8/2018 6:14:21 AM RBC Capital Markets Starts Intra-Cellular Therapies, Inc. (ITCI) At Outperform With $33 Price Target
9/29/2016 6:18:56 AM RBC Capital Markets Is Lowering Intra-Cellular Therapies, Inc. (ITCI) 2018 Estimate To -3.06 From -1.16
9/29/2016 6:18:34 AM RBC Capital Markets Is Cutting Intra-Cellular Therapies, Inc. (ITCI) 2017 Estimate To -3.71 From -3.68
9/29/2016 6:18:17 AM RBC Capital Markets Is Raising Intra-Cellular Therapies, Inc. (ITCI) 2016 Estimate To -3.40 From -3.46
9/29/2016 6:17:43 AM RBC Capital Markets Is Increasing Intra-Cellular Therapies, Inc. (ITCI) Q4 16 Estimate To -1.15 From -1.20